In an effort to align cancer treatment in Pakistan with modern medical advancements and integrate global research into local clinical practice, renowned pharmaceutical company Hamel Pharmaceuticals organized a major national scientific conference in Lahore titled “Molecules to Miracles 2.1.” The event brought together leading oncologists, hematologists, medical experts, and senior physicians from across the country. On this occasion, six new targeted therapy medicines were also launched.
The conference featured detailed discussions on recent advances in the treatment of breast cancer, lung cancer, gastrointestinal cancers, and various blood malignancies. Experts exchanged views on targeted therapies, precision medicine, molecular diagnostics, and emerging treatment strategies.
In their opening remarks, Professor Dr. Kausar Bano, Head of Oncology at Jinnah Hospital Lahore, and Professor Abbas Khokhar emphasized the urgent need to incorporate modern scientific research into routine clinical practice. They stated that such scientific forums not only promote high-quality healthcare but also improve patients’ access to advanced and effective treatment options.
Speaking at the conference, Dr Usman Amin Butt, Director of Hamel Pharmaceuticals, said that cancer treatment is rapidly entering a new era in which precision medicine, molecular testing, and advanced targeted therapies are significantly improving treatment outcomes. He reaffirmed the company’s commitment to strengthening the connection between global medical research and local clinical expertise through the continued organization of such scientific platforms.
During the conference, experts presented scientific findings on new medicines and advanced treatment approaches for breast cancer, lung cancer, gastrointestinal cancers, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Chronic Lymphocytic Leukemia.
Speakers noted that modern targeted therapies and evidence-based treatment strategies are expected to deliver better outcomes and long-term benefits for cancer patients in the future.
Prominent cancer and hematology specialists from various cities across Pakistan attended the conference and shared their experiences, insights, and perspectives on the latest developments in research, treatment, and patient care.
At the conclusion of the event, participants agreed that the future of cancer treatment in Pakistan depends on advanced research, collaboration, precision medicine, and continuous scientific education. They emphasized that ongoing scientific progress and innovative treatment options are opening new doors of hope and improving the quality of life for cancer patients nationwide.